A股异动丨申联生物盘中跌逾6% 股东UBI拟减持不超3%公司股份

Core Viewpoint - Shenyin Biological (688098.SH) experienced a significant intraday drop of 6.31% to 10.24 yuan due to a planned share reduction by a major shareholder, UBI, to meet funding needs for clinical trials and commercialization of innovative drugs, including an Alzheimer's peptide vaccine [1] Summary by Relevant Sections - Shareholder Actions - UBI, a shareholder holding more than 5% of the company, plans to reduce its holdings by up to 4.1064 million shares through centralized bidding and up to 8.2129 million shares through block trading, totaling a maximum reduction of 12.3193 million shares, which represents 3% of the company's total share capital [1] - Purpose of Share Reduction - The share reduction is aimed at funding the clinical trials and commercialization efforts for original innovative drugs, as well as accelerating the construction of manufacturing bases in collaboration with partners in China [1] - Timeline for Share Reduction - The reduction period is set from November 13, 2025, to February 12, 2026, with the shares being sourced from those acquired prior to the IPO [1]